What is the significance of a 3-month-old male's hemoglobin electrophoresis showing Hemoglobin (Hb) S of 25.6% and Hemoglobin (Hb) F of 20.7%, with a previous result 3 months prior showing Hb S of 6.3%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnosis: Sickle Cell Disease (Likely HbSS or HbS-β⁰-thalassemia)

This 3-month-old infant's hemoglobin electrophoresis results are diagnostic of sickle cell disease, with the rising HbS percentage from 6.3% to 25.6% representing the expected physiologic decline in fetal hemoglobin and corresponding increase in HbS production as the infant ages. 1

Understanding the Laboratory Results

  • The initial newborn screen showing HbS 6.3% was obtained when fetal hemoglobin (HbF) was still predominant, which is normal for newborns with sickle cell disease 1
  • The current results at 3 months showing HbS 25.6% and HbF 20.7% reflect the normal developmental transition from fetal to adult hemoglobin production that occurs during the first year of life 1, 2
  • The MCH of 24.4 (low) suggests microcytosis, which could indicate concurrent alpha-thalassemia trait (common in sickle cell patients) or the specific genotype may be HbS-β⁺-thalassemia rather than HbSS 3
  • The absence of HbA on the current electrophoresis strongly suggests either HbSS or HbS-β⁰-thalassemia, both of which are severe forms requiring identical management 1

Immediate Critical Actions Required

1. Urgent Subspecialty Referral

  • Refer immediately to a pediatric hematologist or comprehensive sickle cell center before the infant reaches 3 months of age (this patient is already at that threshold) 1
  • Confirm the exact genotype (HbSS vs HbS-β⁰-thalassemia vs HbS-β⁺-thalassemia vs HbSC) through repeat hemoglobin electrophoresis and parental studies, as this determines disease severity and treatment intensity 1

2. Start Penicillin Prophylaxis Immediately

  • Begin penicillin V potassium 125 mg orally twice daily today to prevent life-threatening pneumococcal septicemia and meningitis 1
  • This should continue until age 3 years, then increase to 250 mg twice daily until at least age 5 years 1
  • Alternative options include amoxicillin 20 mg/kg/day or erythromycin if penicillin allergy 1

3. Emergency Education for Parents

  • Any fever ≥38°C (100.4°F) requires immediate emergency department evaluation within 1 hour for urgent CBC, reticulocyte count, blood culture, and parenteral ceftriaxone before leaving the facility 1
  • Teach parents to palpate the spleen daily and recognize signs of acute splenic sequestration (rapidly enlarging spleen, pallor, weakness), which is a life-threatening emergency requiring immediate transfusion 1
  • Document baseline spleen size at every visit to detect acute changes 1

4. Accelerated Vaccination Schedule

  • Ensure pneumococcal conjugate vaccine (PCV15 or PCV20) series is initiated and completed according to an accelerated schedule for high-risk infants 1
  • Administer meningococcal conjugate vaccine against serotypes A, C, W, and Y at a young age 1

Upcoming Treatment Consideration

  • At 9 months of age, offer hydroxyurea therapy even without clinical symptoms if the genotype is confirmed as HbSS or HbS-β⁰-thalassemia 1
  • Hydroxyurea increases fetal hemoglobin, decreases vaso-occlusive complications, and improves quality of life 1
  • Monitoring requires CBC and reticulocyte count every 1-3 months due to potential myelosuppression 1

Clinical Context of the Laboratory Findings

  • The protective effect of HbF (currently 20.7%) will continue to decline over the first year of life, making the infant increasingly susceptible to sickling complications 2
  • Both HbF and HbA₂ have equivalent sparing effects on HbS polymerization, so the total non-HbS hemoglobin provides some protection 2
  • The low MCH (24.4) may actually provide some additional protection if it reflects concurrent alpha-thalassemia, as lower intracellular hemoglobin concentration reduces sickling tendency 4

Common Pitfalls to Avoid

  • Do not delay penicillin prophylaxis waiting for subspecialty consultation—splenic dysfunction develops early in infancy and septicemia can be rapidly fatal 1
  • Do not reassure parents that the infant is "doing well" without symptoms—the most dangerous complications (septicemia, splenic sequestration) can occur suddenly in previously asymptomatic infants 1
  • Do not assume this is a milder variant (HbSC or HbS-β⁺-thalassemia) without confirmatory testing—the absence of HbA suggests a severe form requiring aggressive prophylaxis 1, 3

References

Guideline

Management of Sickle Cell Disease in Infants

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations.

Proceedings of the National Academy of Sciences of the United States of America, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.